A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
Clinical trial NCT00650793 · COMPLETED
Trial details
- NCT number
- NCT00650793
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2004-03-01
- Enrollment
- 473
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.